Aussie CRO Novotech Expands Asian Footprint With Indian ETI Joint Venture: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
The largest independent contract research organization in Australia, Sydney-based Novotech announced May 6 that it formed a joint venture with Bangalore-based ETI Klinical, which is part of the multinational Karle Group. With operations in Australia, New Zealand, the United States, India and South Korea, Novotech CEO Alek Safarian talked with PharmAsia News' Australia bureau about the joint venture and the company's plans to further expand its footprint in emerging markets in Asia.